Sep 10, 2025, 3:04 PM EDT · 1 year ago Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers
Aug 7, 2025, 4:05 PM EDT · 1 year ago IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery
Feb 24, 2025, 8:15 AM EST · 1 year ago Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
Feb 19, 2025, 9:15 AM EST · 1 year ago Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay
Feb 10, 2025, 9:15 AM EST · 1 year ago Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
Jan 27, 2025, 4:10 PM EST · 1 year ago IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies
Nov 22, 2024, 5:15 PM EST · 1 year ago IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
Nov 14, 2024, 9:10 AM EST · 1 year ago IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)
Sep 19, 2024, 10:00 AM EDT · 2 years ago IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology
2024-07-11T13:22:45.000Z · 2 years ago IMAC Holdings appoints Matthew Schwartz, Peter Beitsch to board
Jul 11, 2024, 9:21 AM EDT · 2 years ago IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors
2024-06-13T20:51:47.000Z · 2 years ago IMAC Holdings files to sell common stock, warrants, no amount given
May 7, 2024, 8:30 AM EDT · 2 years ago IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business
2023-11-24T11:33:38.000Z · 2 years ago IMAC Holdings price target lowered to $10 from $34.50 at Ascendiant
2023-09-27T20:38:22.000Z · 3 years ago IMAC Holdings regains compliance with Nasdaq minimum bid price rule
Sep 27, 2023, 4:30 PM EDT · 3 years ago IMAC Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements
Jul 26, 2023, 9:25 AM EDT · 3 years ago IMAC Holdings Announces $4.3 Million Private Placement of Convertible Preferred Stock and Warrants Priced at the Market
May 30, 2023, 11:04 PM EDT · 3 years ago THERALINK INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Theralink Technologies, Inc. - THER
May 23, 2023, 9:43 AM EDT · 3 years ago Theralink® Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company
Mar 31, 2023, 8:00 PM EDT · 3 years ago IMAC Holdings Reports Year End 2022 Financial Results and Corporate Update
Mar 20, 2023, 7:30 AM EDT · 3 years ago IMAC Holdings and Brain Scientific Announce a Strategic Merger to Create Synergistic End-To-End Neurological Solution
Oct 21, 2022, 10:30 AM EDT · 4 years ago IMAC Holdings, Inc. Hosts Hall of Fame Athlete Panel at the Evoke Conference to Launch Whole Food Supplement Partnership
Sep 9, 2022, 9:22 AM EDT · 4 years ago IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease
Sep 7, 2022, 8:30 AM EDT · 4 years ago Biote Announces Strategic Partnership with IMAC Holdings, Inc. BTMD
Sep 1, 2022, 9:44 AM EDT · 4 years ago IMAC Holdings, Inc. Announces Addition of Medical Weight Loss Services to IMAC Regeneration Centers
Aug 16, 2022, 4:00 PM EDT · 4 years ago IMAC Holdings, Inc. Announces Closing of $3.9 Million Registered Direct and Private Placement Offerings
Aug 15, 2022, 11:30 AM EDT · 4 years ago IMAC Holdings Reports Record Revenue of $5M in Second Quarter
Aug 12, 2022, 9:16 AM EDT · 4 years ago IMAC Holdings, Inc. Announces $3.9 Million Registered Direct and Private Placement
